NFKB1 and cancer: Apart from causing cell cycle arrest, PGV-1 reduced NF-κB activation and lowered cyclooxygenase-2 (COX-2) expression, an NF-κB downstream protein, indicating that PGV-1 might be a beneficial agent for cancer combination therapy [29].